Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (CH:BMY)
:BMY
Nivolumab, Folfox, Pumitamig, Capox
Untreated Advanced Or Metastatic Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma
Phase II/III
Not Yet Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Oct 23, 2025
―
Bevacizumab, Folfiri, Folfox, Pumitamig, Capox
Untreated, Unresectable, Or Metastatic Colorectal Cancer
Phase II/III
Not Yet Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Oct 23, 2025
―
Bms-986506
Renal Cell Carcinoma
Phase I
Not Yet Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Sep 25, 2025
―
Bms-986454
Rheumatoid Arthritis
Phase I
Not Yet Recruiting
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
Sep 11, 2025
―
Gemcitabine, Carboplatin, Eribulin, Pumitamig, Nab-Paclitaxel/Paclitaxel
Breast Neoplasms
Phase III
Not Yet Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Sep 08, 2025
―
Bms-986517
Solid Tumours
Phase I/II
Not Yet Recruiting
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Aug 29, 2025
―
Lamotrigine, Xanomeline/Trospium Chloride, Lithium, Valproate
Bipolar Disorder, Mania
Phase III
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Aug 21, 2025
―
Gemcitabine, Carboplatin, Cisplatin, Iza-Bren
Urothelial Cancer
Phase II/III
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Aug 05, 2025
―
Deucravacitinib, Ustekinumab
Plaque Psoriasis
Phase III
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Aug 04, 2025
―
Pemetrexed, Carboplatin, Cisplatin, Iza-Bren
Non-small Cell Lung Cancer
Phase II/III
Not Yet Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Jul 31, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Bristol-Myers Squibb (BMY) have in its pipeline
BMY is currently developing the following drugs: Nivolumab, Folfox, Pumitamig, Capox, Bevacizumab, Folfiri, Folfox, Pumitamig, Capox, Bms-986506. These drug candidates are in various stages of clinical development as the company works toward FDA approval.